• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cross Country Healthcare Announces Second Quarter 2024 Financial Results

    7/31/24 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary
    Get the next $CCRN alert in real time by email

    Cross Country Healthcare, Inc. (the "Company") (NASDAQ:CCRN) today announced financial results for its second quarter ended June 30, 2024.

    SELECTED FINANCIAL INFORMATION:

     

     

     

    Variance

    Variance

     

     

     

    Q2 2024 vs

    Q2 2024 vs

    Dollars are in thousands, except per share amounts

    Q2 2024

    Q2 2023

    Q1 2024

    Revenue

    $

    339,771

     

     

     

    (37

    )

    %

     

    (10

    )

    %

    Gross profit margin*

     

    20.8

     

    %

     

    (200

    )

    bps

     

    40

     

    bps

    Net (loss) income attributable to common stockholders

    $

    (16,050

    )

     

     

    (175

    )

    %

     

    (696

    )

    %

    Diluted EPS

    $

    (0.47

    )

     

    $

    (1.07

    )

     

    $

    (0.55

    )

     

    Adjusted EBITDA*

    $

    14,178

     

     

     

    (68

    )

    %

     

    (7

    )

    %

    Adjusted EBITDA margin*

     

    4.2

     

    %

     

    (400

    )

    bps

     

    20

     

    bps

    Adjusted EPS*

    $

    0.10

     

     

    $

    (0.59

    )

     

    $

    (0.09

    )

     

    Cash flows provided by operations

    $

    82,401

     

     

     

    (31

    )

    %

     

    1,271

     

    %

    * Represents amounts that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are referred to as non-GAAP measures. Please refer to the accompanying discussion below of how these non-GAAP financial measures are calculated and used under "Non-GAAP Financial Measures" and the tables reconciling these measures to the closest GAAP measure.

    Second Quarter Business Highlights

    • Physician Staffing and Homecare Staffing experienced sequential and year-over-year revenue growth
    • $82.4 million of cash flows from operations for Q2 2024, primarily driven by strong collections
    • Days Sales Outstanding down 7 days year-over-year and 18 days sequentially
    • Continued strong balance sheet with $70 million of cash on hand and no debt as of June 30, 2024
    • Repurchased approximately 980,000 shares of common stock for $14.9 million

    "Our second quarter results were in line with expectations, reflecting our ability to execute in a challenging environment for core nurse and allied. Coming into the back half of the year, I am encouraged by a rise in the level of demand for our services and cautiously optimistic that we are nearing an inflection point in our ability to grow the number of professionals on assignment," said John A. Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, "Additionally, we continue to have a strong pipeline for new business driven by the robustness of Intellify®, our proprietary client-facing workforce solutions platform."

    Second quarter consolidated revenue was $339.8 million, a decrease of 37% year-over-year and 10% sequentially. Consolidated gross profit margin was 20.8%, down 200 basis points year-over-year and up 40 basis points sequentially. Net loss attributable to common stockholders was $16.1 million as compared to net income of $21.3 million in the prior year and $2.7 million in the prior quarter. Diluted loss per share (EPS) was $0.47 as compared to diluted income per share of $0.60 in the prior year and $0.08 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $14.2 million, or 4.2% of revenue, as compared with $44.4 million, or 8.2% of revenue, in the prior year, and $15.3 million, or 4.0% of revenue, in the prior quarter. Adjusted EPS was $0.10, as compared to $0.69 in the prior year and $0.19 in the prior quarter.

    For the six months ended June 30, 2024, consolidated revenue was $718.9 million, a decrease of 38% year-over-year. Consolidated gross profit margin was 20.6%, down 200 basis points year-over-year. Net loss attributable to common stockholders was $13.4 million, or $0.39 per diluted share, as compared to net income of $50.8 million, or $1.41 per diluted share, in the prior year. Adjusted EBITDA was $29.5 million, or 4.1% of revenue, as compared to $96.6 million, or 8.3% of revenue, in the prior year. Adjusted EPS was $0.29, as compared to $1.53 in the prior year.

    Quarterly Business Segment Highlights

    Nurse and Allied Staffing

    Revenue was $291.5 million, a decrease of 41% year-over-year and 12% sequentially. Contribution income was $5.8 million, a decrease from $56.5 million year-over-year and $27.2 million sequentially. Average field contract personnel on a full-time equivalent (FTE) basis was 8,415 as compared with 11,385 in the prior year and 9,124 in the prior quarter. Revenue per FTE per day was $377 as compared to $474 in the prior year and $397 in the prior quarter.

    Physician Staffing

    Revenue was $48.3 million, an increase of 7% year-over-year and 3% sequentially. Contribution income was $4.0 million, an increase from $3.5 million year-over-year and $3.1 million sequentially. Total days filled were 24,252 as compared with 23,826 in the prior year and 23,785 in the prior quarter. Revenue per day filled was $1,992 as compared with $1,902 in the prior year and $1,976 in the prior quarter.

    Cash Flow and Balance Sheet Highlights

    Net cash provided by operating activities for the three months ended June 30, 2024 was $82.4 million, as compared to $119.2 million for the three months ended June 30, 2023 and $6.0 million for the three months ended March 31, 2024. We experienced an 18 day sequential improvement in days' sales outstanding primarily due to robust collections, returning to a more historic level of below 60 days. For the six months ended June 30, 2024, net cash provided by operating activities was $88.4 million as compared to $166.1 million in the prior year.

    During the second quarter, the Company repurchased a total of approximately 980,000 shares of the Company's common stock for an aggregate price of $14.9 million, at an average market price of $15.23 per share. As of June 30, 2024, the Company had 33.4 million unrestricted shares outstanding and $56.0 million remaining for share repurchase.

    As of June 30, 2024, the Company had $69.6 million in cash and cash equivalents with no debt outstanding. There were no borrowings drawn under its revolving senior secured asset-based credit facility (ABL). As of June 30, 2024, borrowing base availability under the ABL was $166.7 million, with $152.9 million of availability net of $13.8 million of letters of credit.

    Outlook for Third Quarter 2024

    The guidance below applies to management's expectations for the third quarter of 2024.

     

    Q3 2024 Range

     

    Year-over-Year

     

    Sequential

    Change

     

    Change

     

     

     

     

     

     

    Revenue

    $305 million - $315 million

     

    (31)% - (29)%

     

    (10)% - (7)%

     

     

     

     

     

     

    Adjusted EBITDA*

    $10.0 million - $13.0 million

     

    (63)% - (52)%

     

    (29)% - (8)%

     

     

     

     

     

     

    Adjusted EPS*

    $0.08 - $0.12

     

    $(0.31) - $(0.27)

     

    $(0.02) - $0.02

    * Refer to discussion of non-GAAP financial measures and the reconciliation tables below.

    The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases.

    INVITATION TO CONFERENCE CALL

    The Company will hold its quarterly conference call on Wednesday, July 31, 2024, at 5:00 P.M. Eastern Time to discuss its second quarter 2024 financial results. This call will be webcast live and can be accessed at the Company's website at ir.crosscountry.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from July 31st through August 14th on the Company's website and a replay of the conference call will be available by telephone by calling 866-360-8701 from anywhere in the U.S. or 203-369-0179 from non-U.S. locations - Passcode: 1703.

    ABOUT CROSS COUNTRY HEALTHCARE

    Cross Country Healthcare, Inc. is a market-leading, tech-enabled workforce solutions and advisory firm with 38 years of industry experience and insight. We help clients tackle complex labor-related challenges and achieve high-quality outcomes, while reducing complexity and improving visibility through data-driven insights. Diversity, equality, and inclusion is at the heart of the organization's overall corporate social responsibility program, and closely aligned with our core values to create a better future for its people, communities, and its stockholders.

    Copies of this and other press releases, as well as additional information about the Company, can be accessed online at ir.crosscountry.com. Stockholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

    NON-GAAP FINANCIAL MEASURES

    This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes such non-GAAP financial measures are useful to investors when evaluating the Company's performance, as such non-GAAP financial measures exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

    In addition, forward-looking adjusted EBITDA and adjusted EPS for fiscal 2024 exclude potential charges or gains that may be recorded during the fiscal year, including among other things, the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases. We have not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of our financial performance.

    FORWARD-LOOKING STATEMENTS

    In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature and/or depend upon or refer to future events. Words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "suggests," "appears," "seeks," "will," "could," and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the overall macroeconomic environment, including increased inflation and interest rates, demand for the healthcare services that we provide, both nationally and in the regions in which we operate, our ability to attract and retain qualified nurses, physicians, and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, including data privacy and protection laws, social, ethical, and security issues relating to the use of artificial intelligence, our customers' ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors, including, without limitation, the risk factors set forth in Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed and updated in our Quarterly Reports on Form 10-Q and other filings with the SEC. You should consult any further disclosures that the Company makes on related subjects in its filings with the SEC.

    Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors' likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements. All references to "the Company," "we," "us," "our," or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its consolidated subsidiaries.

     

    Cross Country Healthcare, Inc.

    Consolidated Statements of Operations

    (Unaudited, amounts in thousands, except per share data)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Six Months Ended

     

    June 30,

     

    June 30,

     

    March 31,

     

    June 30,

     

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

    Revenue from services

    $

    339,771

     

     

    $

    540,695

     

    $

    379,174

     

     

    $

    718,945

     

     

    $

    1,163,402

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    Direct operating expenses

     

    268,966

     

     

     

    417,556

     

     

     

    301,877

     

     

     

    570,843

     

     

     

    900,840

     

    Selling, general and administrative expenses

     

    60,258

     

     

     

    78,938

     

     

     

    63,252

     

     

     

    123,510

     

     

     

    163,198

     

    Credit loss expense

     

    18,858

     

     

     

    3,134

     

     

     

    1,290

     

     

     

    20,148

     

     

     

    8,042

     

    Depreciation and amortization

     

    4,719

     

     

     

    4,432

     

     

     

    4,642

     

     

     

    9,361

     

     

     

    9,336

     

    Restructuring costs

     

    2,116

     

     

     

    913

     

     

     

    938

     

     

     

    3,054

     

     

     

    1,342

     

    Legal and other losses

     

    3,946

     

     

     

    —

     

     

     

    3,650

     

     

     

    7,596

     

     

     

    1,125

     

    Impairment charges

     

    114

     

     

     

    533

     

     

     

    604

     

     

     

    718

     

     

     

    533

     

    Total operating expenses

     

    358,977

     

     

     

    505,506

     

     

     

    376,253

     

     

     

    735,230

     

     

     

    1,084,416

     

    (Loss) income from operations

     

    (19,206

    )

     

     

    35,189

     

     

     

    2,921

     

     

     

    (16,285

    )

     

     

    78,986

     

    Other expenses (income):

     

     

     

     

     

     

     

     

     

    Interest expense

     

    568

     

     

     

    3,149

     

     

     

    462

     

     

     

    1,030

     

     

     

    6,839

     

    Loss on early extinguishment of debt

     

    —

     

     

     

    1,723

     

     

     

    —

     

     

     

    —

     

     

     

    1,723

     

    Other (income) expense , net

     

    (212

    )

     

     

    11

     

     

     

    (1,230

    )

     

     

    (1,442

    )

     

     

    (1

    )

    (Loss) income before income taxes

     

    (19,562

    )

     

     

    30,306

     

     

     

    3,689

     

     

     

    (15,873

    )

     

     

    70,425

     

    Income tax (benefit) expense

     

    (3,512

    )

     

     

    8,961

     

     

     

    997

     

     

     

    (2,515

    )

     

     

    19,644

     

    Net (loss) income attributable to common stockholders

    $

    (16,050

    )

     

    $

    21,345

     

     

    $

    2,692

     

     

    $

    (13,358

    )

     

    $

    50,781

     

     

     

     

     

     

     

     

     

     

     

    Net (loss) income per share attributable to common stockholders - Basic

    $

    (0.47

    )

     

    $

    0.60

     

     

    $

    0.08

     

     

    $

    (0.39

    )

     

    $

    1.43

     

     

     

     

     

     

     

     

     

     

     

    Net (loss) income per share attributable to common stockholders - Diluted

    $

    (0.47

    )

     

    $

    0.60

     

     

    $

    0.08

     

     

    $

    (0.39

    )

     

    $

    1.41

     

     

     

     

     

     

     

     

     

     

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

     

     

    Basic

     

    33,960

     

     

     

    35,351

     

     

     

    34,216

     

     

     

    34,088

     

     

     

    35,606

     

    Diluted

     

    33,960

     

     

     

    35,524

     

     

     

    34,597

     

     

     

    34,088

     

     

     

    36,041

     

     

    Cross Country Healthcare, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (Unaudited, amounts in thousands, except per share data)

     

     

    Three Months Ended

     

    Six Months Ended

     

    June 30,

     

    June 30,

     

    March 31,

     

    June 30,

     

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2024

     

     

     

    2023

     

    Adjusted EBITDA:a

     

     

     

     

     

     

     

     

     

    Net (loss) income attributable to common stockholders

    $

    (16,050

    )

     

    $

    21,345

     

     

    $

    2,692

     

     

    $

    (13,358

    )

     

    $

    50,781

     

    Interest expense

     

    568

     

     

     

    3,149

     

     

     

    462

     

     

     

    1,030

     

     

     

    6,839

     

    Income tax (benefit) expenseb

     

    (3,512

    )

     

     

    8,961

     

     

     

    997

     

     

     

    (2,515

    )

     

     

    19,644

     

    Depreciation and amortization

     

    4,719

     

     

     

    4,432

     

     

     

    4,642

     

     

     

    9,361

     

     

     

    9,336

     

    Acquisition and integration-related costs

     

    —

     

     

     

    64

     

     

     

    —

     

     

     

    —

     

     

     

    46

     

    Restructuring costsc

     

    2,116

     

     

     

    913

     

     

     

    938

     

     

     

    3,054

     

     

     

    1,342

     

    Legal, bankruptcy, and other lossesd

     

    23,319

     

     

     

    —

     

     

     

    3,650

     

     

     

    26,969

     

     

     

    1,125

     

    Impairment chargese

     

    114

     

     

     

    533

     

     

     

    604

     

     

     

    718

     

     

     

    533

     

    Loss on early extinguishment of debtf

     

    —

     

     

     

    1,723

     

     

     

    —

     

     

     

    —

     

     

     

    1,723

     

    Other (income) expense, net

     

    (212

    )

     

     

    11

     

     

     

    (1,230

    )

     

     

    (1,442

    )

     

     

    (1

    )

    Equity compensation

     

    2,259

     

     

     

    2,205

     

     

     

    1,198

     

     

     

    3,457

     

     

     

    3,980

     

    System conversion costsg

     

    857

     

     

     

    1,104

     

     

     

    1,329

     

     

     

    2,186

     

     

     

    1,233

     

    Adjusted EBITDAa

    $

    14,178

     

     

    $

    44,440

     

     

    $

    15,282

     

     

    $

    29,460

     

     

    $

    96,581

     

    Adjusted EBITDA margina

     

    4.2

    %

     

     

    8.2

    %

     

     

    4.0

    %

     

     

    4.1

    %

     

     

    8.3

    %

     

     

     

     

     

     

     

     

     

     

    Adjusted EPS:h

     

     

     

     

     

     

     

     

     

    Numerator:

     

     

     

     

     

     

     

     

     

    Net (loss) income attributable to common stockholders

    $

    (16,050

    )

     

    $

    21,345

     

     

    $

    2,692

     

     

    $

    (13,358

    )

     

    $

    50,781

     

    Non-GAAP adjustments - pretax:

     

     

     

     

     

     

     

     

     

    Acquisition and integration-related costs

     

    —

     

     

     

    64

     

     

     

    —

     

     

     

    —

     

     

     

    46

     

    Restructuring costsc

     

    2,116

     

     

     

    913

     

     

     

    938

     

     

     

    3,054

     

     

     

    1,342

     

    Legal, bankruptcy, and other lossesd

     

    23,319

     

     

     

    —

     

     

     

    3,650

     

     

     

    26,969

     

     

     

    1,125

     

    Impairment chargese

     

    114

     

     

     

    533

     

     

     

    604

     

     

     

    718

     

     

     

    533

     

    Other income, net

     

    —

     

     

     

    —

     

     

     

    (1,115

    )

     

     

    (1,115

    )

     

     

    —

     

    Loss on early extinguishment of debtf

     

    —

     

     

     

    1,723

     

     

     

    —

     

     

     

    —

     

     

     

    1,723

     

    System conversion costsg

     

    857

     

     

     

    1,104

     

     

     

    1,329

     

     

     

    2,186

     

     

     

    1,233

     

    Tax impact of non-GAAP adjustments

     

    (7,066

    )

     

     

    (1,132

    )

     

     

    (1,405

    )

     

     

    (8,471

    )

     

     

    (1,559

    )

    Adjusted net income attributable to common stockholders - non-GAAP

    $

    3,290

     

     

    $

    24,550

     

     

    $

    6,693

     

     

    $

    9,983

     

     

    $

    55,224

     

     

     

     

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

     

     

     

     

    Weighted average common shares - basic, GAAP

     

    33,960

     

     

     

    35,351

     

     

     

    34,216

     

     

     

    34,088

     

     

     

    35,606

     

    Dilutive impact of share-based payments

     

    42

     

     

     

    173

     

     

     

    381

     

     

     

    211

     

     

     

    435

     

    Adjusted weighted average common shares - diluted, non-GAAP

     

    34,002

     

     

     

    35,524

     

     

     

    34,597

     

     

     

    34,299

     

     

     

    36,041

     

     

     

     

     

     

     

     

     

     

     

    Reconciliation:

     

     

     

     

     

     

     

     

     

    Diluted EPS, GAAP

    $

    (0.47

    )

     

    $

    0.60

     

     

    $

    0.08

     

     

    $

    (0.39

    )

     

    $

    1.41

     

    Non-GAAP adjustments - pretax:

     

     

     

     

     

     

     

     

     

    Restructuring costsc

     

    0.06

     

     

     

    0.03

     

     

     

    0.02

     

     

     

    0.08

     

     

     

    0.04

     

    Legal, bankruptcy, and other lossesd

     

    0.69

     

     

     

    —

     

     

     

    0.10

     

     

     

    0.79

     

     

     

    0.03

     

    Impairment chargese

     

    —

     

     

     

    0.01

     

     

     

    0.02

     

     

     

    0.02

     

     

     

    0.01

     

    Other income, net

     

    —

     

     

     

    —

     

     

     

    (0.03

    )

     

     

    (0.03

    )

     

     

    —

     

    Loss on early extinguishment of debtf

     

    —

     

     

     

    0.05

     

     

     

    —

     

     

     

    —

     

     

     

    0.05

     

    System conversion costsg

     

    0.03

     

     

     

    0.03

     

     

     

    0.04

     

     

     

    0.07

     

     

     

    0.03

     

    Tax impact of non-GAAP adjustments

     

    (0.21

    )

     

     

    (0.03

    )

     

     

    (0.04

    )

     

     

    (0.25

    )

     

     

    (0.04

    )

    Adjusted EPS, non-GAAPh

    $

    0.10

     

     

    $

    0.69

     

     

    $

    0.19

     

     

    $

    0.29

     

     

    $

    1.53

     

    Cross Country Healthcare, Inc.

    Consolidated Balance Sheets

    (Unaudited, amounts in thousands)

     

     

    June 30,

     

     

    December 31,

     

     

    2024

     

     

     

     

    2023

     

     

     

     

     

     

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

    $

    69,601

     

     

     

    $

    17,094

     

    Accounts receivable, net

     

    242,333

     

     

     

     

    372,352

     

    Income taxes receivable

     

    8,967

     

     

     

     

    6,898

     

    Prepaid expenses

     

    6,248

     

     

     

     

    7,681

     

    Insurance recovery receivable

     

    8,796

     

     

     

     

    9,097

     

    Other current assets

     

    1,813

     

     

     

     

    2,031

     

    Total current assets

     

    337,758

     

     

     

     

    415,153

     

    Property and equipment, net

     

    29,033

     

     

     

     

    27,339

     

    Operating lease right-of-use assets

     

    2,635

     

     

     

     

    2,599

     

    Goodwill

     

    135,430

     

     

     

     

    135,430

     

    Other intangible assets, net

     

    49,016

     

     

     

     

    54,468

     

    Deferred tax assets

     

    10,064

     

     

     

     

    5,954

     

    Insurance recovery receivable

     

    23,332

     

     

     

     

    25,714

     

    Cloud computing

     

    8,916

     

     

     

     

    5,987

     

    Other assets

     

    6,699

     

     

     

     

    6,673

     

    Total assets

    $

    602,883

     

     

     

    $

    679,317

     

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable and accrued expenses

    $

    55,682

     

     

     

    $

    85,333

     

    Accrued compensation and benefits

     

    46,609

     

     

     

     

    52,297

     

    Operating lease liabilities

     

    2,085

     

     

     

     

    2,604

     

    Earnout liability

     

    4,100

     

     

     

     

    6,794

     

    Other current liabilities

     

    1,639

     

     

     

     

    1,559

     

    Total current liabilities

     

    110,115

     

     

     

     

    148,587

     

    Operating lease liabilities

     

    2,652

     

     

     

     

    2,663

     

    Accrued claims

     

    35,614

     

     

     

     

    34,853

     

    Earnout liability

     

    —

     

     

     

     

    5,000

     

    Uncertain tax positions

     

    11,642

     

     

     

     

    10,603

     

    Other liabilities

     

    3,798

     

     

     

     

    4,218

     

    Total liabilities

     

    163,821

     

     

     

     

    205,924

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

    Common stock

     

    3

     

     

     

     

    4

     

    Additional paid-in capital

     

    215,449

     

     

     

     

    236,417

     

    Accumulated other comprehensive loss

     

    (1,389

    )

     

     

     

    (1,385

    )

    Retained earnings

     

    224,999

     

     

     

     

    238,357

     

    Total stockholders' equity

     

    439,062

     

     

     

     

    473,393

     

    Total liabilities and stockholders' equity

    $

    602,883

     

     

     

    $

    679,317

     

    Cross Country Healthcare, Inc.

    Segment Datai

    (Unaudited, amounts in thousands)

     

     

    Three Months Ended

     

    Year-over-Year

     

    Sequential

     

    June 30,

    % of

     

    June 30,

    % of

     

    March 31,

    % of

     

    % change

     

    % change

     

     

    2024

     

    Total

     

     

    2023

     

    Total

     

     

    2024

     

    Total

     

    Fav (Unfav)

     

    Fav (Unfav)

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services:

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    291,451

     

    86

    %

     

    $

    495,376

    )

    92

    %

     

    $

    332,186

    )

    88

    %

     

    (41

    )%

     

    (12

    )%

    Physician Staffing

     

    48,320

     

    14

    %

     

     

    45,319

     

    8

    %

     

     

    46,988

     

    12

    %

     

    7

    %

     

    3

    %

     

    $

    339,771

     

    100

    %

     

    $

    540,695

     

    100

    %

     

    $

    379,174

     

    100

    %

     

    (37

    )%

     

    (10

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Contribution income:j

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    5,820

     

     

     

    $

    56,481

     

     

     

    $

    27,183

     

     

     

    (90

    )%

     

    (79

    )%

    Physician Staffing

     

    4,033

     

     

     

     

    3,541

     

     

     

     

    3,138

     

     

     

    14

    %

     

    29

    %

     

     

    9,853

     

     

     

     

    60,022

     

     

     

     

    30,321

     

     

     

    (84

    )%

     

    (68

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Corporate overheadk

     

    18,161

     

     

     

     

    18,891

     

     

     

     

    17,566

     

     

     

    4

    %

     

    (3

    )%

    Depreciation and amortization

     

    4,719

     

     

     

     

    4,432

     

     

     

     

    4,642

     

     

     

    (6

    )%

     

    (2

    )%

    Restructuring costsc

     

    2,116

     

     

     

     

    913

     

     

     

     

    938

     

     

     

    (132

    )%

     

    (126

    )%

    Legal and other lossesl

     

    3,946

     

     

     

     

    —

     

     

     

     

    3,650

     

     

     

    (100

    )%

     

    (8

    )%

    Impairment chargese

     

    114

     

     

     

     

    533

     

     

     

     

    604

     

     

     

    79

    %

     

    81

    %

    Other costs

     

    3

     

     

     

     

    64

     

     

     

     

    —

     

     

     

    95

    %

     

    (100

    )%

    (Loss) income from operations

    $

    (19,206

    )

     

     

    $

    35,189

     

     

     

    $

    2,921

     

     

     

    (155

    )%

     

    (758

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Six Months Ended

     

     

     

    Year-over-Year

     

     

     

    June 30,

    % of

     

    June 30,

    % of

     

     

     

    % change

     

     

     

     

    2024

     

    Total

     

     

    2023

     

    Total

     

     

    Fav (Unfav)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services:

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    623,637

     

    87

    %

     

    $

    1,077,678

     

    93

    %

     

     

     

     

    (42

    )%

     

     

    Physician Staffing

     

    95,308

     

    13

    %

     

     

    85,724

     

    7

    %

     

     

     

     

    11

    %

     

     

     

    $

    718,945

     

    100

    %

     

    $

    1,163,402

     

    100

    %

     

     

     

     

    (38

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Contribution income:j

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    33,003

     

     

     

    $

    123,650

     

     

     

     

     

     

    (73

    )%

     

     

    Physician Staffing

     

    7,171

     

     

     

     

    5,265

     

     

     

     

     

     

    36

    %

     

     

     

     

    40,174

     

     

     

     

    128,915

     

     

     

     

     

     

    (69

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Corporate overheadk

     

    35,727

     

     

     

     

    37,547

     

     

     

     

     

     

    5

    %

     

     

    Depreciation and amortization

     

    9,361

     

     

     

     

    9,336

     

     

     

     

     

     

    —

    %

     

     

    Restructuring costsc

     

    3,054

     

     

     

     

    1,342

     

     

     

     

     

     

    (128

    )%

     

     

    Legal and other lossesl

     

    7,596

     

     

     

     

    1,125

     

     

     

     

     

     

    (575

    )%

     

     

    Impairment chargese

     

    718

     

     

     

     

    533

     

     

     

     

     

     

    (35

    )%

     

     

    Other costs

     

    3

     

     

     

     

    46

     

     

     

     

     

     

    93

    %

     

     

    (Loss) income from operations

    $

    (16,285

    )

     

     

    $

    78,986

     

     

     

     

     

     

    (121

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Other costs include acquisition and integration-related costs.

     

     

    Cross Country Healthcare, Inc.

    Summary Condensed Consolidated Statements of Cash Flows

    (Unaudited, amounts in thousands)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Six Months Ended

     

    June 30,

     

    June 30,

     

    March 31,

     

    June 30,

     

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

     

     

     

     

    Net cash provided by operating activities

    $

    82,401

     

     

    $

    119,248

     

     

    $

    6,011

     

     

    $

    88,412

     

     

    $

    166,113

     

    Net cash used in investing activities

     

    (2,849

    )

     

     

    (3,996

    )

     

     

    (2,210

    )

     

     

    (5,059

    )

     

     

    (7,492

    )

    Net cash used in financing activities

     

    (15,193

    )

     

     

    (114,871

    )

     

     

    (15,653

    )

     

     

    (30,846

    )

     

     

    (161,552

    )

    Effect of exchange rate changes on cash

     

    —

     

     

     

    1

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Change in cash and cash equivalents

     

    64,359

     

     

     

    382

     

     

     

    (11,852

    )

     

     

    52,507

     

     

     

    (2,931

    )

    Cash and cash equivalents at beginning of period

     

    5,242

     

     

     

    291

     

     

     

    17,094

     

     

     

    17,094

     

     

     

    3,604

     

    Cash and cash equivalents at end of period

    $

    69,601

     

     

     

    673

     

     

    $

    5,242

     

     

    $

    69,601

     

     

    $

    673

     

     

     

     

     

     

     

     

     

     

     

     

    Cross Country Healthcare, Inc.

    Other Financial Data

    (Unaudited)

     

     

    Three Months Ended

     

    Six Months Ended

     

    June 30,

     

    June 30,

     

    March 31,

     

    June 30,

     

    June 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services

    $

    339,771

     

     

    $

    540,695

     

     

    $

    379,174

     

     

    $

    718,945

     

     

    $

    1,163,402

     

    Less: Direct operating expenses

     

    268,966

     

     

     

    417,556

     

     

     

    301,877

     

     

     

    570,843

     

     

     

    900,840

     

    Gross profit

    $

    70,805

     

     

    $

    123,139

     

     

    $

    77,297

     

     

    $

    148,102

     

     

    $

    262,562

     

    Consolidated gross profit marginm

     

    20.8

    %

     

     

    22.8

    %

     

     

    20.4

    %

     

     

    20.6

    %

     

     

    22.6

    %

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing statistical data:

     

     

     

     

     

     

     

     

     

    FTEsn

     

    8,415

     

     

     

    11,385

     

     

     

    9,124

     

     

     

    8,770

     

     

     

    11,952

     

    Average Nurse and Allied Staffing revenue per FTE per dayo

    $

    377

     

     

    $

    474

     

     

    $

    397

     

     

    $

    388

     

     

    $

    494

     

     

     

     

     

     

     

     

     

     

     

    Physician Staffing statistical data:

     

     

     

     

     

     

     

     

     

    Days filledp

     

    24,252

     

     

     

    23,826

     

     

     

    23,785

     

     

     

    48,037

     

     

     

    45,923

     

    Revenue per day filledq

    $

    1,992

     

     

    $

    1,902

     

     

    $

    1,976

     

     

    $

    1,984

     

     

    $

    1,867

     

    (a)

    Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, other expense (income), net, equity compensation, and system conversion costs. Adjusted EBITDA is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

    (b)

    The decrease in income tax expense for the three and six months ended June 30, 2024 related to a decrease in book income primarily driven by credit loss expense.

    (c)

    Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.

    (d)

    Includes legal costs and other settlement charges as presented on the consolidated statements of operations, losses pertaining to matters outside the normal course of operations, and $19.4 million of credit loss expense driven by a bankruptcy filing by a single large customer for the three and six months ending June 30, 2024. There is no significant impact on operations from this client as the majority of the business had been wound down in the prior year.

    (e)

    Impairment charges for the six months ended June 30, 2024 were related to right-of-use assets and related property in connection with vacated leases during 2024. Impairment charges for the six months ended June 30, 2023 related to the write-off of an abandoned IT project.

    (f)

    Loss on early extinguishment of debt for the three and six months ended June 30, 2023 consisted of the write-off of debt issuance costs related to the payoff and termination of the term loan on June 30, 3023.

    (g)

    System conversion costs include enterprise resource planning system costs related to the upgrading and integrating of our middle and back-office platforms, with certain development costs capitalized and amortized in accordance with the Company's policies, and applicant tracking system costs related to the Company's project to replace its legacy system supporting its travel nurse staffing business.

    (h)

    Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, system conversion costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes Adjusted EPS provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company than EPS. Quarterly non-GAAP adjustment may vary due to rounding.

    (i)

    Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification.

    (j)

    Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

    (k)

    Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and Company-wide projects (initiatives).

    (l)

    Legal and other losses includes legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations.

    (m)

    Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

    (n)

    FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

    (o)

    Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

    (p)

    Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

    (q)

    Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240730815399/en/

    Get the next $CCRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCRN

    DatePrice TargetRatingAnalyst
    12/10/2024Outperform → Mkt Perform
    Barrington Research
    12/6/2023Mkt Perform
    JMP Securities
    11/3/2023$32.00 → $21.00Buy → Hold
    Jefferies
    6/26/2023Outperform
    William Blair
    3/10/2023$30.00Buy
    Loop Capital
    10/5/2022$36.00Buy → Hold
    Truist
    2/24/2022$33.00 → $42.00Buy
    Benchmark
    1/27/2022$18.00 → $27.00Hold → Buy
    Jefferies
    More analyst ratings

    $CCRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cross Country downgraded by Barrington Research

      Barrington Research downgraded Cross Country from Outperform to Mkt Perform

      12/10/24 9:21:19 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • JMP Securities initiated coverage on Cross Country

      JMP Securities initiated coverage of Cross Country with a rating of Mkt Perform

      12/6/23 7:33:30 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country downgraded by Jefferies with a new price target

      Jefferies downgraded Cross Country from Buy to Hold and set a new price target of $21.00 from $32.00 previously

      11/3/23 7:41:51 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cross Country Healthcare Announces First Quarter 2025 Financial Results

      Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408       (23 ) %   (5 ) % Gross profit margin*   20.0   %   (40 ) bps   —   bps Net loss attributable to common stockholders $ (490 )     (118 ) %   87   % Diluted EPS $ (0.02 )   $ (0.10 )

      5/7/25 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

      Cross Country Healthcare, Inc. ("Cross Country" or the "Company") (NASDAQ:CCRN) today announced that the Company has obtained all requisite stockholder approvals in connection with its proposed acquisition by Aya Healthcare. As previously disclosed, Cross Country and Aya Healthcare expect to complete the transaction in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the NASDAQ. Cross Country will file the final, certified voting results on a Form 8-K with the U.S. Securities and Exch

      2/28/25 4:48:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Aya Healthcare to Acquire Cross Country Healthcare for Approximately $615 Million in Cash

      Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr

      12/4/24 7:45:00 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Financials

    Live finance-specific insights

    See more
    • Cross Country Healthcare Announces First Quarter 2025 Financial Results

      Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408       (23 ) %   (5 ) % Gross profit margin*   20.0   %   (40 ) bps   —   bps Net loss attributable to common stockholders $ (490 )     (118 ) %   87   % Diluted EPS $ (0.02 )   $ (0.10 )

      5/7/25 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare to Hold Third Quarter 2024 Earnings Conference Call on Wednesday, November 6, 2024

      Cross Country Healthcare, Inc. (NASDAQ:CCRN) will hold its quarterly conference call to discuss its third quarter 2024 financial results on Wednesday, November 6, 2024 at 5:00 p.m. Eastern Time. Cross Country Healthcare, Inc. (the "Company") intends to distribute its earnings press release after market close on Wednesday, November 6, 2024. This call will be webcast live and can be accessed at the Company's website at ir.crosscountry.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations – Passcode: Cross Country. A replay of the webcast will be available from November 6th through November 20th on the Company's website and a replay of the

      10/18/24 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Announces Second Quarter 2024 Financial Results

      Cross Country Healthcare, Inc. (the "Company") (NASDAQ:CCRN) today announced financial results for its second quarter ended June 30, 2024. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q2 2024 vs Q2 2024 vs Dollars are in thousands, except per share amounts Q2 2024 Q2 2023 Q1 2024 Revenue $ 339,771       (37 ) %   (10 ) % Gross profit margin*   20.8   %   (200 ) bps   40   bps Net (loss) income attributable to common stockh

      7/31/24 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Group President, Delivery Krug Marc S. covered exercise/tax liability with 5,649 shares, decreasing direct ownership by 14% to 34,853 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:44:41 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Chief Financial Officer Burns William J. covered exercise/tax liability with 13,465 shares, decreasing direct ownership by 5% to 242,508 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:43:42 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • General Counsel and Secretary Ball Susan E covered exercise/tax liability with 9,386 shares, decreasing direct ownership by 5% to 176,032 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:43:08 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cross Country Healthcare Inc.

      SCHEDULE 13G - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      5/9/25 12:24:57 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Cross Country Healthcare Inc.

      10-Q - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

      5/7/25 4:45:32 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

      5/7/25 4:28:50 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cash W Larry bought $61,320 worth of shares (6,000 units at $10.22), increasing direct ownership by 3% to 199,632 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      12/31/24 5:15:10 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      11/13/24 9:39:57 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      11/13/24 4:36:10 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Cross Country Healthcare Inc. (Amendment)

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      2/13/24 5:02:31 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Aya Healthcare to Acquire Cross Country Healthcare for Approximately $615 Million in Cash

      Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr

      12/4/24 7:45:00 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • Cross Country Healthcare Appoints Phillip Noe as Chief Information Officer

      Cross Country Healthcare, Inc., (NASDAQ:CCRN), a leading provider of advisory and workforce solutions including contingent staffing, permanent placement, and other consultative services for healthcare clients, has appointed Phillip Noe to the role of Chief Information Officer (CIO). Noe replaces Bill Halnon who is retiring, and will report directly to Kevin C. Clark, Co-founder and CEO. He commences May 10, 2021. "Phil's appointment reflects the ongoing evolution of our digital transformation at Cross Country," said Kevin C. Clark, Co-founder and Chief Executive Officer of Cross Country Healthcare. "His extensive experience in information technology spans every aspect of the software engin

      5/10/21 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary